References
Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32(12): 1123–34
Savage RL, Highton J, Boyd IW, et al. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006; 36(3): 162–9
Searles G, McKendry RJR. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors: four case reports and a review of the literature. J Rheumatol 1987; 14: 1164–71
Smolen JS, Graninger WB, Emery P. Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story [editorial]. Rheumatology 2000; 39: 689–92
Kamata Y, Nara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004; 43(12): 1201–4
Takeishi M, Akiyama Y, Akiba H, et al. Leflunomideinduced interstitial pneumonia. J Rheumatol 2005; 32: 1160–3
Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54(5): 1435–9
Hill RL, Topliss DJ, Purcell PM. Pancytopenia associated with leflunomide and methotrexate [letter]. Ann Pharmacother 2003; 37: 149
Chan J, Sanders DC, Du L, et al. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 2004; 38(7-8): 1206–11
McEwen J, Purcell PM, Hill RL, et al. The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. Pharmacoepidemiol Drug Saf 2007; 16(1): 65–73
Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42(7): 1322–8
Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004; 64: 5804–11
Kis E, Nagy T, Jani M, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis 2009; 68(7): 1201–7
Jenks KA, Stamp LK, O’Donnell JL, et al. Leflunomideassociated infections in rheumatoid arthritis. J Rheumatol 2007; 34(11): 2201–3
European Medicines Agency. EMEA public statement on leflunomide (Arava): pancytopenia and serious skin reactions [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/press/pus/3163799EN.pdf [Accessed 2010 Apr 6]
Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137(9): 726–33
Acknowledgements
The author gratefully acknowledges the comments and advice provided by Dr John McEwen, Discipline of Pharmacy, University of Canberra, Canberra, ACT, Australia, and Associate Professor James Paxton, Head, Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.
The New Zealand Pharmacovigilance Centre is funded by Medsafe, New Zealand Ministry of Health. No sources of funding were used to assist in the preparation of this commentary. The author has no actual or potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Savage, R.L. Leflunomide in Combination Therapy for Rheumatoid Arthritis. Drug-Safety 33, 523–526 (2010). https://doi.org/10.2165/11532390-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11532390-000000000-00000